Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers
NCT ID: NCT01647867
Last Updated: 2018-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
56 participants
INTERVENTIONAL
2012-07-31
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Breath Analysis to Diagnose Lung Cancer
NCT03250390
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
NCT04790682
Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy
NCT06974097
Lung Tumor Protein Synthesis Rates in Lung Cancer Patients
NCT05794529
Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer
NCT04589013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Blood sample collection before bronchoscopy or before surgery, at the same time as a usual blood assessment.
* Prospective collection of bronchial biopsies of patients with metastatic non small cell lung cancer, during a bronchoscopy at the Oscar Lambret Center (Dr Dansin)
* Prospective collection of resected specimens of patients with localized non small cell lung cancer, who were operated at the thoracic surgery unit of the University hospital (Pr Porte)
* Transportation of the samples to the pathology laboratories (Dr Robin, Pr Copin)
* Selection of blocks of interest and preparation of tumor samples
* Clinical data collection : date of biopsy or surgery, disease-free survival, overall survival, tumor characteristics, EGFR status, ALK, BRAF, HER2
* Transportation of tumor blocks and blood samples to the Institute of Biology of Lille for analyses: Western blot, immunohistochemistry and ELISA test)
* Return to storage of the tumor samples at the Oscar Lambret Center and at the University hospital of Lille
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Met analysis
Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test
Met analysis on tissue and blood
10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Met analysis on tissue and blood
10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients candidate for bronchial biopsies at the Oscar Lambret Center (metastatic stage) or candidate for thoracic surgery at University Hospital of Lille (localized stage)
* Treatment naive patient for metastatic NSCLC
* Patients with or without neoadjuvant therapy for localized NSCLC
* Male or female patients aged ≥ 18 years
* Patient registered with the social security system
* Having signed a written Informed Consent
Exclusion Criteria
* Small-cell malignant tumors
* Secondary bronchial lesions
* Revision surgery
* Pregnant or breastfeeding women
* Patient under guardianship or tutorship
* Previous cancer
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Oscar Lambret
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric DANSIN, MD
Role: STUDY_DIRECTOR
Centre Oscar Lambret
David TULASNE, PhD
Role: STUDY_DIRECTOR
Institute of Biology of Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Régional et Universitaire
Lille, , France
Oscar Lambret Center
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MetLung - 1204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.